Trial Profile
Phase II Multicenter Stratified Study Evaluating the Efficacy and Toxicity of Sorafenib in Treating Locally Advanced or Metastatic Angiosarcomas That Are Not Accessible to Curative Surgery
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Haemangiosarcoma
- Focus Therapeutic Use
- 11 Oct 2016 Results of ancillary analysis assessing the prognostic value of biomarkers for progression-free survival presented at the 41st European Society for Medical Oncology Congress
- 17 Apr 2009 New trial record